RecruitingPhase 1NCT07195175
Study of MAR002 in Healthy Men
First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men
Sponsor
Marea Therapeutics
Enrollment
45 participants
Start Date
Aug 11, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 40 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called MAR002 and a drug called Placebo for people with acromegaly. The study is currently recruiting participants at 1 location. People eligible for this study include men aged 18 Years to 40 Years.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMAR002
subcutaneous injection
DRUGPlacebo
Subcutaneous injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07195175
Related Trials
A Study to Evaluate MAR002 for Acromegaly
NCT07641179
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
NCT0693062572 locations
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
NCT075835635 locations
Genetics of Endocrine Tumours - Familial Isolated Pituitary Adenoma - FIPA
NCT004611883 locations
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
NCT0703742045 locations